- Home
- CIK vs CRDF Comparison
CIK vs CRDF Comparison
Compare CIK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- CRDF
- Stock Information
- Founded
- CIK 1987
- CRDF 1999
- Country
- CIK United States
- CRDF United States
- Employees
- CIK N/A
- CRDF N/A
- Industry
- CIK Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIK Finance
- CRDF Health Care
- Exchange
- CIK Nasdaq
- CRDF Nasdaq
- Market Cap
- CIK 162.8M
- CRDF 144.4M
- IPO Year
- CIK N/A
- CRDF N/A
- Fundamental
- Price
- CIK $3.00
- CRDF $2.05
- Analyst Decision
- CIK
- CRDF Strong Buy
- Analyst Count
- CIK 0
- CRDF 5
- Target Price
- CIK N/A
- CRDF $11.10
- AVG Volume (30 Days)
- CIK 115.4K
- CRDF 1.1M
- Earning Date
- CIK 01-01-0001
- CRDF 11-06-2025
- Dividend Yield
- CIK 9.03%
- CRDF N/A
- EPS Growth
- CIK N/A
- CRDF N/A
- EPS
- CIK N/A
- CRDF N/A
- Revenue
- CIK N/A
- CRDF $545,000.00
- Revenue This Year
- CIK N/A
- CRDF N/A
- Revenue Next Year
- CIK N/A
- CRDF N/A
- P/E Ratio
- CIK N/A
- CRDF N/A
- Revenue Growth
- CIK N/A
- CRDF N/A
- 52 Week Low
- CIK $2.50
- CRDF $1.90
- 52 Week High
- CIK $3.19
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- CIK 61.32
- CRDF 36.50
- Support Level
- CIK $2.94
- CRDF $2.03
- Resistance Level
- CIK $2.98
- CRDF $2.27
- Average True Range (ATR)
- CIK 0.02
- CRDF 0.12
- MACD
- CIK 0.00
- CRDF 0.04
- Stochastic Oscillator
- CIK 100.00
- CRDF 31.91
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.